Neutralization of tumor-derived soluble Glucocorticoid-Induced TNFR-Related Protein ligand increases NK cell anti-tumor reactivity

被引:45
作者
Baltz, Katrin M. [1 ]
Krusch, Matthias [1 ]
Baessler, Tina [1 ]
Schmiedel, Benjamin J. [1 ]
Bringmann, Anita [1 ,2 ]
Brossart, Peter [1 ,2 ]
Salih, Helmut R. [1 ]
机构
[1] Univ Tubingen, Dept Hematol & Oncol, D-72076 Tubingen, Germany
[2] Univ Bonn, Dept Hematol & Oncol, D-5300 Bonn, Germany
关键词
D O I
10.1182/blood-2008-03-143016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
NK cell anti-tumor reactivity is governed by a balance of activating and inhibitory receptors including various TNF receptor (TNFR) family members. Here we report that human tumor cells release a soluble form of the TNF family member Glucocorticoid-Induced TNFR-Related Protein (GITR) ligand (sGITRL), which can be detected in cell culture supernatants. Tumor-derived sGITRL concentration-dependently reduced NK cell cytotoxicity and IFN-gamma production, which could be overcome by neutralization of sGITRL using a GITR-Ig fusion protein. Although sGITRL did not induce apoptosis in NK cells, it diminished nuclear localized ReIB, indicating that sGITRL negatively modulates NK cell NF-kappa B activity. Furthermore, we detected substantial levels of sGITRL in sera of patients with various malignancies, but not in healthy controls. Presence of sGITRL-containing patient serum in cocultures with tumor cells significantly reduced NK cell cytotoxicity and IFN-gamma production, which could again be restored by neutralization of sGITRL. The strong correlation of tumor incidence and elevated sGITRL levels indicates that sGITRL is released from cancers in vivo, leading to impaired NK cell immunosurveillance of human tumors. Our data suggest that determination of sGITRL levels might be implemented as a tumor marker in patients, and GITRL neutralization may be used to improve immunotherapeutic strategies relying on NK cell reactivity. (Blood. 2008; 112:3735-3743)
引用
收藏
页码:3735 / 3743
页数:9
相关论文
共 38 条
[1]   Signalling pathways of the TNF superfamily: A double-edged sword [J].
Aggarwal, BB .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (09) :745-756
[2]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[3]   Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions [J].
Baltz, Katrin M. ;
Krusch, Matthias ;
Bringmann, Anita ;
Brossart, Peter ;
Mayer, Frank ;
Kloss, Mercedes ;
Baessler, Tina ;
Kumbier, Ingrid ;
Peterfi, Andrea ;
Kupka, Susan ;
Kroeber, Stefan ;
Menzel, Dagmar ;
Radsak, Markus P. ;
Rammensee, Hans-Georg ;
Salih, Helmut R. .
FASEB JOURNAL, 2007, 21 (10) :2442-2454
[4]   Glucocorticoid-induced tumour necrosis factor receptor (GITR) and its ligand (GITRL) in atopic dermatitis [J].
Baumgartner-Nielsen, Jane ;
Vestergaard, Christian ;
Thestrup-Pedersen, Kristian ;
Deleuran, Mette ;
Deleuran, Bent .
ACTA DERMATO-VENEREOLOGICA, 2006, 86 (05) :393-398
[5]   Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L [J].
Calmels, B ;
Paul, S ;
Futin, N ;
Ledoux, C ;
Stoeckel, F ;
Acres, B .
CANCER GENE THERAPY, 2005, 12 (02) :198-205
[6]   Agonist anti-GITR antibody enhances vaccine-induced CD8+ T-cell responses and tumor immunity [J].
Cohen, AD ;
Diab, A ;
Perales, MA ;
Wolchok, JD ;
Rizzuto, G ;
Merghoub, T ;
Huggins, D ;
Liu, CL ;
Turk, MJ ;
Restifo, NP ;
Sakaguchi, S ;
Houghton, AN .
CANCER RESEARCH, 2006, 66 (09) :4904-4912
[7]   Interferons, immunity and cancer immunoediting [J].
Dunn, Gavin P. ;
Koebel, Catherine M. ;
Schreiber, Robert D. .
NATURE REVIEWS IMMUNOLOGY, 2006, 6 (11) :836-848
[8]   Glucocorticoid-induced TNF receptor, a costimulatory receptor on naive and activated T cells, uses TNF receptor-associated factor 2 in a novel fashion as an inhibitor of NF-κB activation [J].
Esparza, EM ;
Arch, RH .
JOURNAL OF IMMUNOLOGY, 2005, 174 (12) :7875-7882
[9]   Human natural killer cell development and biology [J].
Farag, Sherif S. ;
Caligiuri, Michael A. .
BLOOD REVIEWS, 2006, 20 (03) :123-137
[10]   Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation [J].
Groh, V ;
Wu, J ;
Yee, C ;
Spies, T .
NATURE, 2002, 419 (6908) :734-738